Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Saltarelli is in the catbird seat...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by narmacon Jan 10, 2023 10:13am
132 Views
Post# 35213209

RE:RE:RE:RE:Saltarelli is in the catbird seat...

RE:RE:RE:RE:Saltarelli is in the catbird seat...Saltarelli is excited???,,,,,not from his body language in the webinar,,,,looks like he is sedated,,,,and or going thru the motions for the camera,,,,,no mattter,,he gets paid with no skin in the game and couldnt give a rats behind what comes of any of it,,,,,,he is there only for his name,,isnt it obvious,,,,,he was just as excited when interviewed with Bioasis,,,looked like it was past his bed time!!,,Pitiful!!!

The only win here for us would be if xB3 does not work,,,if it does its white collar crime all around!!

Vote No,,,,!!!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities